2001 was an important year for Chiron. We continued our growth as a profitable global company by delivering strong financial results. Those results underscore once again our commitment to leverage our diverse business model to develop and commercialize high-value products that make a difference in people’s lives. The year was also important for the focused investment we made to position Chiron for sustainable growth in the future. With the approval of the board, we have implemented strategic imperatives that will guide our growth and development. We are bringing a sharp focus to the work that we do. Our capabilities are focused around two areas of biological activity—cancer and infectious disease. We are applying our advanced understanding of the biology of cancer and infectious disease to developing products from three platforms—proteins, small molecules, and vaccines. And we are aligning our research programs with our three global businesses. With this vision for Chiron, we will be able to build on the progress we made in 2001..